The DLX3 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the human DLX3 gene. This heterogeneous pool provides loss-of-function alleles, enabling versatile functional studies without clonal bias. The knockout is established in the HAP1 cell line, a near-haploid platform derived from KBM-7 chronic myeloid leukemia cells, combining genetic simplicity with robust growth.
HAP1 cells possess a near-haploid karyotype that facilitates efficient gene editing and unambiguous genotype-phenotype correlations. Originally derived from a male CML patient, this cell line is widely adopted for functional genomics screens, drug-gene interaction studies, and mechanistic investigations. Its stable haploid state ensures reliable knockout analysis and supports high-throughput applications.
DLX3 encodes a homeobox transcription factor central to epidermal differentiation, hair follicle morphogenesis, and osteogenesis. The protein functions downstream of the Wnt/??-catenin pathway, where ??-catenin/LEF1 complexes promote its expression; it is also regulated by BMP4/SMAD1/5/8 and Notch/HES1 cascades. DLX3 directly targets differentiation genes such as KRT14, involucrin, filaggrin, loricrin, and osteocalcin. It interacts with cofactors including p300, CBP, and TP63 to orchestrate transcriptional programs. Canonical ligands WNT3A and WNT10B stabilize ??-catenin, which partners with LEF1 to activate DLX3 transcription. BMP4 engages BMPR1A and SMAD1/5/8 to induce DLX3, while Notch activation through NOTCH1 and HES1 further controls its expression. DLX3 then transcriptionally regulates a suite of structural genes: basal keratin KRT14, suprabasal KRT1, and cross-linked envelope components. Interacting proteins like MSX1, p300, and TP63 fine-tune its activity, integrating multiple signaling inputs to coordinate terminal differentiation programs.
In the HAP1 near-haploid leukemic context, DLX3 disruption eliminates a transcription factor that, although normally associated with epithelial lineages, can be ectopically expressed and influence proliferation and apoptosis pathways. The polyclonal population yields a collection of loss-of-function genotypes, each with potentially distinct effects on downstream networks. This diversity enhances the robustness of drug sensitivity measurements and permits the identification of subtle modulatory interactions. Coupled with the ease of genome manipulation in HAP1, this model accelerates genome-wide CRISPR screens, synthetic lethality studies, and chemical genetic profiling of DLX3-related signaling.
These knockout cells are ideal for functional genomics screens to dissect genetic interactions in Wnt, BMP, and Notch pathways, as well as for investigating differentiation processes. Typical experimental workflows include RT-qPCR and RNA-seq to profile transcriptional changes, Luciferase reporter assays to validate target gene regulation, and proliferation or drug sensitivity assays to explore therapeutic responses. The model is particularly relevant to disorders such as tricho-dento-osseous syndrome, amelogenesis imperfecta, and other ectodermal dysplasias. For detailed protocols or ordering information, please contact Ascent Research.
